Company news

Novartis AG news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

October 17, 2025

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)

October 16, 2025

NCCN Awards Funding to Improve Care for People with Breast Cancer

October 1, 2025

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

September 30, 2025

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US

September 29, 2025

Novartis announces commencement of tender offer to acquire Tourmaline Bio

September 29, 2025

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025

September 26, 2025

Regenerative Medicine Industry Trends and Growth Strategies, 2025-2030 Featuring Novartis, Biogen, GlaxoSmithKline, Baxter International, and Boehringer Ingelheim

September 25, 2025

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

September 24, 2025

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

September 15, 2025

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

September 9, 2025

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)

September 9, 2025

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

September 2, 2025

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

August 30, 2025

Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance

August 21, 2025

New Novartis ESC data highlights strength of cardiovascular portfolio

August 18, 2025

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

August 12, 2025

← Newer news releases

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 39 decks. Every deck is listed under its year.